REX CHAN: Open Payments
NPI 1821583576 · FOLSOM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$344 in 11 payments from 10 companies in 2025. Trend: 2023 $704 · 2024 $4,192 · 2025 $344
Food & beverage: $344
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 2 | $112 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Incyte Corporation | 1 | $30 |
| PFIZER INC. | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
| SERVIER PHARMACEUTICALS LLC | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
Products named: Lenvima, Nubeqa, Enhertu, JAKAFI, XTANDI, LYNPARZA, SCEMBLIX, XPOVIO.
Industry payments across CA — which companies pay providers there.
